Skip to main content
ABCL logo

ABCL · AbCellera Biologics Inc.

Track ABCL — free
$11.02 -0.01 (-0.09%) At close · Nov 18
Market Cap
$3.60B
Shares
326.62M
Volume · Nov 18 2.59M Avg daily vol (3M) 4.51M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.02 Open$11.16 Day$10.96–11.55 52W close$2.78–14.82 Avg vol 30d3.6M Short int29.0M · 8.9% of shares · 8.5d Short vol51% Last earningsNov 9, 2026 DataDec 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 17
Investor event
Hot flash candidate ABCL635 shows twice small-molecule efficacy

AbCellera says its phase two ABCL635 hot flash trial showed roughly twice the frequency reduction of small-molecule NK3R antagonists at four weeks; 12-week data is due early 2027.

5 source passages
the most exciting program is the lead asset, ABCL635, which is a first-in-class antibody antagonist of NK3R So in our readout, we showed that at four weeks, so a single dose and then at four weeks efficacy that is roughly twice as good in reducing the frequency of hot flashes over the current market leaders, which are small molecule NK3R antagonists So this 12-week data, what you're going to see is a diminishing of efficacy in the active group which you recently confirmed will occur in early 2027 Open the document at this passage
Nov 16
Investor event
ABCL635 efficacy supports planned late-stage development

AbCellera Biologics Inc. said ABCL635 achieved twice the frequency and four to five times the severity efficacy of approved small molecules, with a clean safety profile supporting planned late-stage development.

2 source passages
And the most exciting one is our lead asset, which is ABCL635. So we just had our phase two readout in August and Basically, the data blew the doors off, so we've got efficacy that is twice as good in frequency as the small molecules that are approved, four to five times as good in severity, a clean safety profile, and we are now getting ready to engage with the regulators and bring that into late-stage studies next year Open the document at this passage
Nov 11
Investor event
50% hot-flash reduction supports ABCL 635 late-stage development

ABCL said its ABCL 635 produced a 50% placebo-controlled hot-flash reduction in a 92-patient trial, with a clean safety profile and evidence supporting once monthly dosing, and is preparing for late stage development.

4 source passages
So we've made a transition recently, and I think we're going to talk today about ABCL 635. We showed in that data, which was a study of about 92 patients, one-to-one placebo-controlled, that we had a 50% placebo-controlled reduction in hot flashes. And we got all of that with a clean safety profile and a PK-PD relationship that looks like it supports the TPP of once monthly. And certainly we'll be moving into late stage studies for menopausal VMS next year. Open the document at this passage
Nov 9
Earnings call
ABCL635 phase-two results support planned 2027 development

ABCL635 showed a 50% placebo-adjusted reduction in moderate-to-severe hot-flash frequency in Phase 2. Abcelera plans late-stage development in 2027, raised $200 million, and ended the quarter with over $790 million in cash and marketable securities.

5 source passages
Q3 was a transformative quarter for Abcelera, driven primarily by our positive top-line phase two results for ABCL635 Expressed as a percent change from baseline, the ABCL635 group experienced an 83% reduction from baseline in daily events compared to a 33% reduction in the placebo group for a placebo-adjusted treatment difference of 50%. We expect to initiate late-stage development for menopause, VMS, in 2027. Following the release of our Phase 2 data for ABCL 635, we completed a significantly oversubscribed $200 million capital raise. Altogether we finished the quarter with over $790 million of cash and marketable securities. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ABCL635 met Phase 2 endpoints for menopausal hot flashes

AbCellera reported that ABCL635 met primary Phase 2 efficacy endpoints, with a 5.3 placebo-adjusted treatment difference in daily moderate and severe hot flashes (p<0.001), and plans late-stage development in 2027.

Revenue $10.64M ▲ 18.8% Net loss $40.76M Diluted EPS -$0.13
Read from the MD&A section
4 source passages
In August 2026, we announced positive top-line results from the Phase 2 portion of our Phase 1/2 clinical trial evaluating ABCL635. The study met the primary efficacy endpoints achieving statistically significant reductions in both frequency and severity of VMSM-S at week 4 compared to placebo after a single dose. ABCL635 reduced VMSM-S frequency compared to placebo, with an 8.8 mean reduction in the number of moderate and severe events per day from baseline at week 4 (Day 29) compared to 3.5, showing a mean placebo-adjusted treatment difference of 5.3 (p<0.001). We expect to initiate late-stage development of ABCL635 for menopausal VMS in 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$67.86M
Trailing 12 months
Net income (TTM)
−$148.29M
Trailing 12 months
Revenue growth YoY
+18.8%
Year over year
Operating margin
-298.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.4%
Year over year · more shares
Price change (1Y)
+201.1%
Trailing year
Short interest
8.9%
Latest settlement · 8.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. ABCL635 delivered strong Phase 2 efficacy and favorable tolerability, with 2027 development plans, a $200 million capital raise, an expanded pipeline, and over $890 million of available liquidity. ABCL575 will stop after Phase 1, ABCL635 efficacy is expected to decline during washout, the partner-program count fell from 44 to 34, and nine-month revenue and net loss worsened versus the prior-year period.

Bullish
Bearish
  • − Although ABCL575 met its Phase 1 endpoints with favorable tolerability and pharmacokinetics, AbCellera does not plan to develop it beyond Phase 1. new
  • − ABCL635 efficacy is expected to decline during the final eight-week washout, and the company does not expect efficacy to be maintained through 12 weeks after a single dose. new
  • − The number of partner-led programs believed to be progressing and in which AbCellera holds a downstream stake fell to 34 from 44 at December 31, 2025. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Very Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +50%
above
Price vs 50-day avg −11%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 68%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −10%
trailing
6-month return +79%
trailing
YTD return +222%
this year
Relative strength +82%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $12 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +46 funds added
Insider flow Accumulating
Net +$667.9K over 90 days · 0% sells
Short interest Falling
8.89% of shares out · ▼ -6.2% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
167 holders — near 3-yr high, broad support
Squeeze score 71
high risk · 0–100
Fundamentals
Strong
Revenue growth +161%
Y/Y
EPS growth +11%
Y/Y
Free cash flow $-174.1M
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −40%
past year
ATR 7.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+50% Bullish
Price vs 50-day avg
−11% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
68% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $12 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +46 funds added
Insider flow Accumulating
Net +$667.9K over 90 days · 0% sells
Short interest Falling
8.89% of shares out · ▼ -6.2% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
167 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $11 · 68% Range high $15
vs 200-day avg +50% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
available liquidity to execute on our strategy $790M As of September 30, 2026 —
Available non-dilutive government funding $100M Q3 2026 —
Complete resolution of VMSM-S 37% Week 4 (data cutoff 30JUL26) —
Molecules in the clinic with downstream stakes 12 September 30, 2026 —
total cash balances & marketable securities $100M As of September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABCL
AbCellera Biologics Inc.
this stock
$3.60B +222.2% +160.6% — 8.9%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
167
% held
40.2%
Net QoQ
+15.1M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
31
View
Short & Settlement
Short Interest Falling
Shares short
29.0M
Days to cover
8.5d
Change
-1.9M sh
View
Short Volume
Short vol %
51%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
13.1K
Value
$178.6K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$667.9K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$75.1M
Net income (FY)
$-146.4M
EPS diluted
$-0.49
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
26

AbCellera says its phase two ABCL635 hot flash trial showed roughly twice the frequency reduction of small-molecule NK3R antagonists at four weeks; 12-week data is due early 2027.

View
Exempt Offerings
Offering
$74.5M
Filed
May 27, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
AbCellera Reports Q3 2026 Busines…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
ABCL -7.8% -10.0% +78.6% -10.2% +222.2%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -3.9% -4.4% +82.1% -6.8% +215.1%
Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 172 filings 162 filers Visit website Investor relations